The interaction isn't necessarily dangerous, but it requires dosing adjustments and close monitoring
The evidence here is nuanced and worth exploring in detail
Busetto concludes: "In this analysis of individuals with obesity aged 65 years and older, semaglutide reduced body weight and improved cardiometabolic risk factors compared with placebo, and the safety and efficacy profile of semaglutide was consistent with that reported in the STEP program." He adds: "In many countries, including many high-income countries, the majority of the cases of excess weight actually occur in adults aged 65 years and over, representing a major driver for obesity-related complications and an important cause of reduced quality of life and disability
Slim Care, Your Local Partner in Weight Loss At Slim Care, we believe losing weight doesnt have to be complicated

Practical Checklist Before Enrolling in Amble Before starting an intake with Amble or any GLP-1 telehealth platform, a woman should have the following information available: Current weight and height (BMI calculation) List of all medications, including oral contraceptives, metformin, or any insulin Recent labs within the past 12 months, including TSH, HbA1c, and a metabolic panel if available Documentation of any prior weight-loss pharmacotherapy, including which agent, dose, and reason for stopping Clarity on monthly budget including both platform fee and pharmacy cost Understanding that she will need to self-administer a subcutaneous injection weekly and store the pen correctly (refrigerated at 2-8 degrees Celsius) A woman who checks all these boxes, meets BMI criteria, has no contraindications, and can sustain the financial commitment for 12-24 months is a genuinely appropriate candidate for a GLP-1 program through a platform like Amble